Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | WNT1 | P04628 | 4/20 | 0.53 |
| ▸ | GSK3B | P49841 | 4/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17450650 | 0.99 | RAB9A (0.56) | RAB9AMAPTNPC1HPGDTSHR | |
| SCHEMBL17450648 | 0.89 | ALDH1A1 (0.60) | RAB9AMAPTTSHRMEN1KMT2A | |
| SCHEMBL15986800 | 0.87 | RAB9A (0.53) | RAB9AMAPTNPC1TSHRMEN1 | |
| SCHEMBL21676988 | 0.87 | RAB9A (0.53) | RAB9AMAPTNPC1TSHRMEN1 | |
| SCHEMBL15743960 | 0.87 | TSHR (0.72) | TSHRMEN1KMT2AALDH1A1WNT1 | |
| SCHEMBL18998184 | 0.87 | RAB9A (0.53) | RAB9AMAPTNPC1TSHRMEN1 | |
| SCHEMBL21676901 | 0.86 | KDM4E (0.58) | RAB9AMAPTHPGDTSHRMEN1 | |
| SCHEMBL17409785 | 0.86 | DRD4 (0.56) | RAB9AMAPTNPC1TSHRMEN1 | |
| SCHEMBL15986799 | 0.85 | WNT1 (0.56) | RAB9AMAPTNPC1TSHRMEN1 | |
| SCHEMBL15986675 | 0.83 | TSHR (0.52) | NPC1TSHRKDM4EALDH1A1WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730878-B2 | Fused quinoline compounds as PI3K/mTOR inhibitors | Advenchen Pharmaceuticals, LLC (US) | 2020-08-04 | — | — | US | disclosed |
| EP-3319602-B1 | FUSED QUINOLINE COMPOUNDS AS PI3K/MTOR INHIBITORS | ADVENCHEN PHARMACEUTICALS LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3169687-B1 | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | ADVENCHEN PHARMACEUTICALS NANJING LTD (CN) | 2019-01-02 | — | — | EP | disclosed |
| US-20180201613-A1 | FUSED QUINOLINE COMPUNDS AS PI3K/mTOR INHIBITORS | Advenchen Pharmaceuticals, LLC (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180201613-A1 | FUSED QUINOLINE COMPUNDS AS PI3K/mTOR INHIBITORS | Advenchen Pharmaceuticals, LLC (US) | 2018-07-19 | — | — | US | disclosed |
| US-20170174687-A1 | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | ADVENCHEN PHARMACEUTICALS NANJING LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| US-20170174687-A1 | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | ADVENCHEN PHARMACEUTICALS NANJING LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| WO-2017011363-A1 | FUSED QUINOLINE COMPUNDS AS PI3K/MTOR INHIBITORS | Advenchen Pharmaceuticals, LLC (US) | 2017-01-19 | — | — | WO | disclosed |
| WO-2016010869-A2 | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | Advenchen Pharmaceuticals, LLC (US) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174687-A1 | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | MTOR, RICTOR, PIK3CA | RAB9A 168/4885MAPT 1744/4885NPC1 1601/4885 |
| US-10730878-B2 | Fused quinoline compounds as PI3K/mTOR inhibitors | MTOR, RICTOR, PIK3CA | RAB9A 178/4885MAPT 1886/4885NPC1 1565/4885 |
| US-20180201613-A1 | FUSED QUINOLINE COMPUNDS AS PI3K/mTOR INHIBITORS | MTOR, RICTOR, PIK3CA | RAB9A 217/4885MAPT 1748/4885NPC1 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.